collaborative
research
opgen
group
company
ares
genetics
johns
hopkins
researchers
demonstrates
potential
sequencing
investigation
genetic
antimicrobial
resistance
mec
published
study
modifiable
risk
factors
emergence
resistance
presented
study
sequencing
predict
phenotypic
antimicrobial
susceptibility
testing
results
work
aimed
demonstrating
diagnostic
value
sequencing
antimicrobial
susceptibility
testing
translation
clinical
practice
vienna
austria
gaithersburg
globe
newswire
opgen
nasdaq
opgn
opgen
announced
today
scientists
subsidiary
ares
genetics
gmbh
vienna
austria
ares
genetics
collaboration
researchers
johns
hopkins
university
school
medicine
published
study
modifiable
risk
factors
emergence
resistance
aeruginosa
journal
clinical
infectious
diseases
aeruginosa
listed
world
health
organization
critical
priority
pathogen
overcome
antimicrobial
resistance
introduced
novel
inhibitor
combination
agent
received
initial
fda
approval
investigations
indicated
activity
approximately
canadian
aeruginosa
isolates
soon
clinical
introduction
reports
resistance
therapy
emerged
study
published
clinical
infectious
diseases
sought
understand
mechanisms
resistance
leading
resistance
frequency
novel
inhibitor
combinations
identify
modifiable
risk
factors
may
slow
prevent
acquisition
resistance
findings
demonstrate
potential
sequencing
ngs
investigate
mechanisms
resistance
analyzing
sequencing
data
aeruginosa
isolates
developed
resistance
treatment
mutations
identified
resistant
isolates
involved
amongst
others
ampc
known
binding
site
ceftolozane
target
ceftolozane
dna
polymerase
researchers
propose
extending
infusions
potential
protective
measure
acquired
mutational
resistance
present
study
result
ongoing
collaboration
ares
genetics
johns
hopkins
university
school
medicine
goal
investigating
diagnostic
potential
ngs
antimicrobial
susceptibility
testing
earlier
year
patricia
simner
johns
hopkins
medicine
ares
genetics
presented
results
study
assessing
potential
sequencing
predict
antimicrobial
susceptibility
results
online
asm
microbe
meeting
andreas
posch
ceo
ares
genetics
studies
commented
already
shown
ngs
allows
identification
bacterial
pathogens
antimicrobial
resistance
markers
well
accurate
prediction
phenotypic
resistance
previous
publications
present
studies
underline
diagnostic
value
ngs
well
need
rapid
antimicrobial
resistance
testing
improving
antibiotic
treatment
regiments
particularly
excited
joint
work
using
sequencing
technology
phenotype
prediction
technology
could
potentially
allow
molecular
antibiotic
susceptibility
testing
directly
native
patient
samples
opgen
opgen
gaithersburg
md
usa
precision
medicine
company
harnessing
power
molecular
diagnostics
bioinformatics
help
combat
infectious
disease
along
subsidiaries
curetis
gmbh
ares
genetics
gmbh
developing
commercializing
molecular
microbiology
solutions
helping
guide
clinicians
rapid
actionable
information
life
threatening
infections
improve
patient
outcomes
decrease
spread
infections
caused
microorganisms
mdros
opgen
product
portfolio
includes
unyvero
acuitas
amr
gene
panel
lighthouse
ares
technology
platform
including
aresdb
using
ngs
technology
bioinformatics
solutions
antibiotic
response
prediction
information
please
visit
statements
opgen
press
release
includes
statements
regarding
studies
publications
opgen
subsidiary
ares
genetics
gmbh
statements
statements
regarding
opgen
future
plans
goals
constitute
statements
within
meaning
section
securities
act
section
securities
exchange
act
intended
qualify
safe
harbor
liability
established
private
securities
litigation
reform
act
statements
subject
risks
uncertainties
often
difficult
predict
beyond
control
may
cause
results
differ
materially
expectations
factors
could
cause
results
differ
materially
described
include
limited
ability
successfully
timely
develop
seek
obtain
regulatory
clearance
commercialize
product
services
offerings
rate
adoption
products
services
hospitals
healthcare
providers
realization
expected
benefits
business
combination
transaction
curetis
gmbh
success
commercialization
efforts
impact
company
operations
financial
results
commercialization
efforts
well
capital
markets
general
economic
conditions
effect
business
existing
new
regulatory
requirements
economic
competitive
factors
discussion
significant
risks
uncertainties
associated
opgen
business
please
review
filings
securities
exchange
commission
cautioned
place
undue
reliance
statements
based
expectations
date
press
release
speak
date
press
release
undertake
obligation
publicly
update
revise
statement
whether
result
new
information
future
events
otherwise
opgen
contact
oliver
schacht
ceo
investorrelations
press
contact
matthew
bretzius
fischtank
marketing
pr
matt
investor
contact
megan
paul
edison
group
mpaul
